Excluded:
1529 women with switching between different types of endocrine therapy Excluded:
(a) 4593 (52%) women who were general beneficiaries (b) 40 (0.4%) women who were treated with exemestane monotherapy Supplementary Table 1 Rx-Risk-V medicine groups included in study. Median follow up (Q1, Q3) 2.6 (1.0, 4.6) 2.6 (1.0, 4.6) 2.6 (0.9, 4.5) 3.0 (1.3, 5.0) Supplementary Table 3 Incidence rates for each type of comorbidity in women with and without breast cancer (stratified by type of endocrine therapy). 
Rx-Risk-V class Medication classes/medications ATC codes/PBS codes

